Takunda Macharaga’s Post

Now live on our website! Don't miss your chance to learn more about and register for our upcoming webinar: Accelerating Market Access of New Medicines. By the end of this free, digital event, participants will 📌 Understand the role of compassionate use programs in providing access to new medicines with limited clinical data. 📌 Explore strategies to expedite the national evaluation process for new medicines in low and middle-income countries. Participants will also receive a digital certificate of attendance following completion of the webinar. Follow the link below to learn more and register! #gmdpacademy #medicalaffairs #gmdpacademy #medicinesdevelopment #NDA #newdrugapplication #pharma #pharmaceuticaldevelopment #marketaccess #webinar #continuingeducation #continuouslearning

Denmark’s Novo Nordisk and its US rival Eli Lilly could become the world’s first trillion-dollar Healthcare companies! 🔊 So says Gemma Game (Healthcare strategist at Norway’s sovereign wealth fund, the world’s largest). Novo has a bit to go yet, but it’s more than halfway there, with Europe’s most valuable company last week exceeding a market value of $500 billion (€460bn) after reporting better-than-expected 2023 earnings. Like Lilly, Novo’s success is driven by soaring demand for its anti-obesity and diabetes drugs, #Ozempic & #Wegovy Novo’s overall sales soared 36 per cent last year and growth of 18 to 26 per cent is expected for 2024!🚀 Eli Lilly, meanwhile, is the largest pharmaceutical company in the world by market value, which currently stands at roughly $612 billion. Novo Nordisk Eli Lilly and Company #pharmamanufacturing #pharmajobs #pharmatech #healthcare

Have you ever been challenged to explain the value your Medical Affairs team is delivering to the external & internal stakeholders? Have you ever struggled to do it, while it was so obvious to you? If you have the same experience, please join us in the discussion at #NEXT Pharma Summit!

Investing in Novo Nordisk: Capitalizing on a Surging Stock Summary: Novo Nordisk, a leading pharmaceutical company specializing in diabetes care, has experienced impressive growth in the stock market throughout this year, consistently outperforming the broader market. With its remarkable performance, there are strong indications that now is an opportune time to consider investing in Novo Nordisk. Why Novo Nordisk is Still a Buy: 1. Unstoppable Growth: Novo Nordisk's stock has surged this year, demonstrating its resilience and ability to deliver exceptional returns even during challenging times. 2. Dominance in Diabetes Care: The company's unwavering focus on diabetes treatments and innovations in the field has solidified its position as a market leader. With the prevalence of diabetes continuing to rise globally, Novo Nordisk is well-positioned to capture significant market share and sustain long-term growth. 3. Robust Pipeline: Novo Nordisk's ongoing commitment to research and development has resulted in a robust pipeline of potential blockbuster drugs. This innovative approach ensures a continuous stream of high-quality products, driving future revenue growth and shareholder value. 4. Stable Financials: Despite market volatility, Novo Nordisk has showcased consistent financial performance, generating substantial revenues and maintaining healthy profit margins. This stability provides investors with confidence in the company's ability to weather economic uncertainties. Take Action Now - Don't Miss Out! Investing in Novo Nordisk allows you to align your financial goals with a company making a tangible impact on global health. By capturing the potential for substantial returns and supporting advancements in diabetes care, you can enhance not only your wealth but also contribute to the well-being of countless individuals worldwide. #HSA #investing #healthcare #health #family #wellness 💪💰🔥 Click here now to seize this opportunity, secure your financial future, and make a positive impact!

On World Pharmacy Day, I celebrate Colonel Eli Lilly, a pharmacist born in 1838. His experiences in the Civil War inspired him to revolutionize medical care. In 1876, he founded Eli Lilly and Company in Indianapolis, prioritizing scientific rigor and quality control when many medicines were unreliable. The company's innovations, like mass-manufactured insulin in the 1920s, have transformed healthcare, particularly in diabetes treatment. Beyond business success, Eli Lilly was a dedicated philanthropist, supporting hospitals, education, and his community. Today, Eli Lilly and Company remains a global pharmaceutical leader, upholding its founder's legacy by developing groundbreaking medications that enhance healthcare and improve lives. #WorldPharmacyDay #PharmaceuticalInnovation #HealthcareAdvancements

AstraZeneca announces another strong set of results for Q2 and upgrades the full year revenue and EPS guidance. Oncology remains a strong pillar driving sales growth in high double digits. A move into oral agents for obesity looks interesting with an oral GLP-1 agent and two others with novel modes of action that are likely to be positioned for obesity patients with co-morbidities such as hypertension and Chronic Kidney Disease. By 2030, AstraZeneca aims to double revenue to $80 billion. And unlike others that make claims, AZ says "how" it will realise these aspirations. Today, based on a global revenue of $40 billion, the AZ share price is £120. I can't wait to see the share price with a revenue of $80 billion! Sadly, this Labour Government will rob me with Capital Gains Tax, which they will surely raise in this Autumn's budget (double the tax rate to 20% and 40% for higher rate taxpayers). Robbing bar stewards!

Eli Lilly Chair and CEO Dave Ricks has helped disrupt the healthcare industry with the company’s obesity drugs, but he hopes and predicts that the next decade of transformative medicines will focus on brain health. Dave notes how the science is much more tractable now for neurodegenerative conditions than it has been in the past, and how the world’s most valuable pharmaceutical company is investing in and prioritizing treatments for Parkinson’s, ALS, Alzheimer’s, and more. Listen to Dave's insights on advancing “the last frontier” of brain health, breakthroughs in diabetes and obesity drugs, and more on our recent #GoldmanSachsTalks: https://lnkd.in/eSg6tQaD

The transformation of pharma from an industry perceived as one putting profit before people to one with patients front and center is underway, but we still need to accelerate partnerships to reach the ultimate end goal. Download Reuters brand new white paper to learn more: https://bit.ly/4c6NdnB Hear from Boehringer Ingelheim, Novartis, Deloitte, ViiV Healthcare and more to stay ahead of the curve when it comes to patient-centric care in the months to come!

The transformation of pharma from an industry perceived as one putting profit before people to one with patients front and center is underway, but we still need to accelerate partnerships to reach the ultimate end goal. Download Reuters brand new white paper to learn more: https://bit.ly/3WEv9N4 Hear from Boehringer Ingelheim, Novartis, Deloitte, ViiV Healthcare and more to stay ahead of the curve when it comes to patient-centric care in the months to come!

Publication of NIBRT’s Annual Report 2023 NIBRT today published its Annual Report for 2023 which highlights a 7% growth in revenue bringing research and training activity to the highest level in the Institute’s history. The success of the Irish biopharma industry is well documented, with biopharma firmly established as a key pillar of the Irish economy. There are 84,000 highly skilled people directly and indirectly employed in the sector and the expectation is that this will increase by up to 10,000 jobs over the next 5 years. 2023 saw continued strong performance of the sector with significant new developments including Astellas, Lilly, MSD, Novo Nordisk and others. NIBRT continued its strong support of the sector throughout 2023 with some of the key achievements in the year including: • A 7% growth in overall revenue, bringing research and training activity to the highest level in the Institute’s history. • 9% increase in training activity with client companies based in Ireland. • 28% growth in research activity, underpinned by the joint appointment of new Principal Investigators in partnership with Irish and international universities. • The signing of two new NIBRT global partnerships in the US. • The opening of the Advanced Therapies building and the CONCEPT facilities. Download and read full press release here -https://hubs.la/Q02j66Fd0